These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34185331)

  • 1. Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy.
    Pillai VC; Shah M; Rytting E; Nanovskaya TN; Wang X; Clark SM; Ahmed MS; Hankins GDV; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2022 Jan; 88(1):271-281. PubMed ID: 34185331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy.
    Chen J; You X; Wu W; Guo G; Lin R; Ke M; Huang P; Lin C
    Eur J Pharm Sci; 2023 Feb; 181():106349. PubMed ID: 36496167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.
    Alqahtani S; Kaddoumi A
    PLoS One; 2015; 10(10):e0139762. PubMed ID: 26431339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.
    Liu XI; Momper JD; Rakhmanina N; van den Anker JN; Green DJ; Burckart GJ; Best BM; Mirochnick M; Capparelli EV; Dallmann A
    J Clin Pharmacol; 2020 Feb; 60(2):240-255. PubMed ID: 31489678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Maternal and Fetoplacental Concentrations of Cefazolin, Cefuroxime, and Amoxicillin during Pregnancy Using Bottom-Up Physiologically Based Pharmacokinetic Models.
    Abduljalil K; Ning J; Pansari A; Pan X; Jamei M
    Drug Metab Dispos; 2022 Apr; 50(4):386-400. PubMed ID: 35046066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Framework to Predict Maternal-Placental-Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach.
    Werdan Romão MA; Pinto L; Cavalli RC; Duarte G; de Moraes NV; Abduljalil K; Moreira FL
    J Clin Pharmacol; 2024 May; 64(5):568-577. PubMed ID: 38305718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis.
    Zhang H; Kalluri HV; Bastian JR; Chen H; Alshabi A; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2018 Sep; 84(9):2075-2087. PubMed ID: 29873094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Verification of a Linked
    Patilea-Vrana GI; Unadkat JD
    Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach.
    Van Der Heijden JEM; Van Hove H; Van Elst NM; Van Den Broek P; Van Drongelen J; Scheepers HCJ; De Wildt SN; Greupink R
    Am J Obstet Gynecol; 2024 May; ():. PubMed ID: 38763343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy.
    Salem F; Nguyen D; Bush M; Moore KP; Mudunuru J; Stamatopoulos K; Thakkar N; Taskar KS
    CPT Pharmacometrics Syst Pharmacol; 2024 May; ():. PubMed ID: 38690782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.
    Gaohua L; Abduljalil K; Jamei M; Johnson TN; Rostami-Hodjegan A
    Br J Clin Pharmacol; 2012 Nov; 74(5):873-85. PubMed ID: 22725721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy.
    Chen Y; Ke M; Fang W; Jiang Y; Lin R; Wu W; Huang P; Lin C
    Eur J Pharm Sci; 2024 Mar; 194():106707. PubMed ID: 38244810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome.
    van Hoogdalem MW; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
    Pharmacol Ther; 2022 Jun; 234():108045. PubMed ID: 34813863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling.
    Roelofsen D; van Hove H; Bukkems V; Russel F; Eliesen G; Greupink R
    Toxicol In Vitro; 2022 Dec; 85():105471. PubMed ID: 36096459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester.
    Shenkoya B; Atoyebi S; Eniayewu I; Akinloye A; Olagunju A
    Front Pediatr; 2021; 9():734122. PubMed ID: 34616699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy.
    Abduljalil K; Pansari A; Jamei M
    J Pharmacokinet Pharmacodyn; 2020 Aug; 47(4):361-383. PubMed ID: 32840724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus.
    Szeto KX; Le Merdy M; Dupont B; Bolger MB; Lukacova V
    AAPS J; 2021 Jun; 23(4):89. PubMed ID: 34169370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.
    De Sousa Mendes M; Lui G; Zheng Y; Pressiat C; Hirt D; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Urien S; Benaboud S
    Clin Pharmacokinet; 2017 May; 56(5):537-550. PubMed ID: 27766562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Caffeine Disposition in Pregnancy.
    Darakjian LI; Kaddoumi A
    Mol Pharm; 2019 Mar; 16(3):1340-1349. PubMed ID: 30689395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy.
    Xia B; Heimbach T; Gollen R; Nanavati C; He H
    AAPS J; 2013 Oct; 15(4):1012-24. PubMed ID: 23835676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.